NDAORALTABLET
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
LIVALO (pitavastatin calcium) by Kowa Pharmaceuticals is 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase, the enzyme that catalyzes the conversion of hmg-coa to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. First approved in 2009.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVALO (pitavastatin calcium) is an oral HMG-CoA reductase inhibitor (statin) approved in 2009 for cholesterol management. It works by inhibiting the rate-limiting enzyme in hepatic cholesterol synthesis, thereby increasing LDL receptor expression and reducing plasma LDL and VLDL levels. Pitavastatin is indicated for patients with elevated cholesterol who require lipid-lowering therapy.
$0.19BPart D
LOE ApproachingDeclining
As LOE approaches, the brand faces significant generic erosion; commercial team focus shifts toward managed care optimization and lifecycle extension rather than growth initiatives.
Mechanism of Action
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes
Started Oct 2022
1,538 enrolled
Hypercholesterolemia
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet
Started Jan 2013
52 enrolled
HyperlipidemiaHypertension
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
Started Aug 2011
48 enrolled
HyperlipidemiaHypertension
Livalo Acute Myocardial Infarction Study (LAMIS)
Started Jul 2010
1,000 enrolled
Acute Myocardial Infarction
Livalo Acute Myocardial Infarction Study
Started Apr 2007
1,128 enrolled
Acute Myocardial Infarction
Worked on LIVALO at Kowa Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.